The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) is a key kinase regulating cell growth and survival.
• mTOR signaling is implicated in multiple myeloma proliferation, invasion, and chemoresistance.
• mTOR is a validated therapeutic target for anti-cancer drug discovery.

Purpose of the Study:

• To review advances in drug discovery targeting the mTOR signaling pathway for multiple myeloma treatment.
• To highlight the clinical potential of mTOR inhibitors in multiple myeloma and other cancers.
• To incorporate recent study findings on mTOR-targeted therapies.

Main Methods:

• Literature review of mTOR signaling in multiple myeloma.
• Analysis of mTOR inhibitors in pre-clinical and clinical studies.
• Synthesis of recent research data on mTOR-targeted drug discovery.

Main Results:

• mTOR pathway dysregulation is crucial in multiple myeloma pathogenesis.
• Numerous mTOR inhibitors have been developed with significant anti-cancer activity.
• mTOR inhibitors show considerable clinical potential for multiple myeloma treatment.

Conclusions:

• Targeting the mTOR pathway is a viable strategy for multiple myeloma therapy.
• Ongoing drug discovery is yielding promising mTOR inhibitors for cancer treatment.
• Further research into mTOR-targeted therapies could improve patient outcomes in multiple myeloma.